Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer.
HIV reservoir
anti-HIV immune responses
compensatory mechanisms
immune checkpoint blockade
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
17 03 2022
17 03 2022
Historique:
received:
01
02
2022
revised:
03
03
2022
accepted:
09
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
13
4
2022
Statut:
epublish
Résumé
The role of immune checkpoints (ICPs) in both anti-HIV T cell exhaustion and HIV reservoir persistence, has suggested that an HIV cure therapeutic strategy could involve ICP blockade. We studied the impact of anti-PD-1 therapy on HIV reservoirs and anti-viral immune responses in people living with HIV and treated for cancer. At several timepoints, we monitored CD4 cell counts, plasma HIV-RNA, cell associated (CA) HIV-DNA, EBV, CMV, HBV, HCV, and HHV-8 viral loads, activation markers, ICP expression and virus-specific T cells. Thirty-two patients were included, with median follow-up of 5 months. The CA HIV-DNA tended to decrease before cycle 2 (
Identifiants
pubmed: 35326466
pii: cells11061015
doi: 10.3390/cells11061015
pmc: PMC8946896
pii:
doi:
Substances chimiques
Antiviral Agents
0
CTLA-4 Antigen
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Virology. 2019 Oct;536:16-19
pubmed: 31394407
AIDS. 2018 Jul 17;32(11):1491-1497
pubmed: 29746296
J Neurol. 2021 Jul;268(7):2458-2465
pubmed: 33515299
AIDS. 2016 Mar 13;30(5):761-9
pubmed: 26730568
Immunity. 2017 Oct 17;47(4):776-788.e5
pubmed: 29045906
PLoS One. 2013 May 22;8(5):e63818
pubmed: 23717490
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282824
J Med Virol. 2009 Feb;81(2):217-23
pubmed: 19107966
J Clin Microbiol. 2000 Apr;38(4):1404-8
pubmed: 10747115
J Virol. 2008 Jan;82(1):435-50
pubmed: 17942551
J Infect Dis. 2017 Jun 1;215(11):1725-1733
pubmed: 28431010
J Immunol. 2011 May 15;186(10):5854-62
pubmed: 21460204
Clin Infect Dis. 2021 Oct 5;73(7):e1973-e1981
pubmed: 33677480
Mol Immunol. 2001 Dec;38(6):467-73
pubmed: 11741696
Cancers (Basel). 2021 Oct 31;13(21):
pubmed: 34771650
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Immunol Methods. 2004 Feb 1;285(1):71-87
pubmed: 14871536
J Hepatol. 2019 Nov;71(5):900-907
pubmed: 31306680
Nat Commun. 2019 Feb 18;10(1):814
pubmed: 30778080
AIDS. 2009 Oct 23;23(16):2079-89
pubmed: 19710595
J Immunol. 2020 Mar 1;204(5):1242-1254
pubmed: 31988180
Microbes Infect. 2005 Apr;7(4):626-34
pubmed: 15820153
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8
pubmed: 22549384
Blood. 2008 Feb 1;111(3):1387-95
pubmed: 18000163
J Exp Med. 2005 Jun 20;201(12):1999-2010
pubmed: 15967826
AIDS. 2015 Feb 20;29(4):504-6
pubmed: 25628259
Ann Oncol. 2018 Apr 1;29(4):1067-1069
pubmed: 29324995
PLoS Pathog. 2016 Jul 14;12(7):e1005761
pubmed: 27415008
Vaccines (Basel). 2019 Oct 12;7(4):
pubmed: 31614877
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Lancet. 1996 Oct 26;348(9035):1133-8
pubmed: 8888167
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Nature. 2009 Mar 12;458(7235):206-10
pubmed: 19078956
Clin Vaccine Immunol. 2006 Jun;13(6):684-97
pubmed: 16760328
J Immunol. 2007 Aug 1;179(3):1979-87
pubmed: 17641065
PLoS One. 2019 Oct 22;14(10):e0224211
pubmed: 31639143
AIDS. 2020 Feb 1;34(2):167-175
pubmed: 31634190
Ann Oncol. 2018 Feb 1;29(2):517-518
pubmed: 29206889
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
J Virol. 2004 Jun;78(11):5707-19
pubmed: 15140968
Lancet HIV. 2015 Mar;2(3):e82-91
pubmed: 26424549